Pharmacological Management of Germinal Matrix-Intraventricular Hemorrhage
- Author:
Jaewoo CHUNG
1
;
Sang Koo LEE
;
Chun-Sung CHO
;
Young Jin KIM
;
Jung Ho KO
;
Jung-Ho YUN
;
Jin-Shup SO
;
In-Ho JUNG
Author Information
- Publication Type:Review Article
- From:Journal of Korean Neurosurgical Society 2023;66(3):258-262
- CountryRepublic of Korea
- Language:English
- Abstract: Germinal matrix-intraventricular hemorrhage (GM-IVH) is among the devastating neurological complications with mortality and neurodevelopmental disability rates ranging from 14.7% to 44.7% in preterm infants. The medical techniques have improved throughout the years, as the morbidity-free survival rate of very-low-birth-weight infants has increased; however, the neonatal and long-term morbidity rates have not significantly improved. To this date, there is no strong evidence on pharmacological management on GM-IVH, due to the limitation of well-designed randomized controlled studies. However, recombinant human erythropoietin administration in preterm infants seems to be the only effective pharmacological management in limited situations. Hence, further high-quality collaborative research studies are warranted in the future to ensure better outcomes among preterm infants with GM-IVH.
